Next Phase Newsletter

One of the largest medical equipment companies in China is specialized in R&D, manufacturing and distribution of medical equipment. The firm is looking globally for collaboration, in-licensing, and M&A opportunities in medtech innovations that has a China angle. The firm typically seeks distribution rights in the Chinese market.

Within medtech, the firm is looking for technologies that can complement its existing product lines in respiratory system, circulatory system, endocrine system, home care, and hospital equipment. The firm has a special interest in disposable medical materials, digital devices, respiratory care equipment, and sleep monitoring technologies. The firm prefers class I and 510k devices that are within 1-2 years to FDA clearance.

The firm is seeking innovative technologies that can address unmet medical need in the Chinese market. The firm can utilize its manufacturing facilities to reduce production cost and leverage a marketing network and distribution channels of more than 150 service centers all over the country.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A South Korean pharmaceutical company that specializes in Gastrointestinal, CNS, and Metabolic products is actively searching for promising therapeutic candidates under development around the world to incorporate into its pipeline. The company is flexible in terms of the structure, but mostly in-licensing or co-development. The company is interested in world wide/major territories such as the US, EU, APAC, and East Asia.

The firm is currently seeking promising therapeutic candidates to incorporate into its pipeline. The company is most interested in neurology, hepatology, and gastroenterology. However, the firm is also interested in other therapeutic areas that address large unmet medical needs. The company will look at both small molecules and biologics and will consider only NCE or NCE-like molecules (such as repositioning molecule, new indication, etc). The company prefers assets in phase I, II, or IND-ready. However, the company will also look at assets in phase III and NDA stage.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in the Southern United States is currently seeking new investments in healthcare companies. The firm makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to invest in syndicates. The firm primarily invests in companies that are based in the Southern U.S. but is open to opportunities across North America. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, healthcare IT, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a large pharmaceutical company is mandated to invest directly in private early-stage life science companies with promising new products that may be future pipeline candidates. The firm seeks to invest across the more expansive business footprint of its parent company. The firm has a global mandate and is currently seeking new equity investment opportunities.

The firm is particularly interested in therapies for rare diseases, oncology, vaccines, and immune mediated diseases. The firm will also invest in breakthrough product candidates in other therapeutic areas such as cardiovascular and diabetes.  The firm seeks products that are in preclinical or early clinical development and that have proof-of-concept data. The firm also willing to consider medical devices targeting these indication

The firm generally co-invests with top tier life science investors and looks to take a minority position (<20%) in each portfolio company. The firm seeks to be a long-term investor with board responsibilities either as a full seat or as an observer.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The Corporate Venture arm of a Hi-Tech Company current manages a total of $850 million in assets, and is looking to make equity investments ranging from $2-$5 million with the ability to allocate up to $10 million generally in series A-C rounds. The majority of fund’s investment have been throughout the United States although they have and are willing to invest internationally as well. The fund is actively reviewing new opportunities can could make 3-4 investments over the next year.

The Fund is currently interested in sectors of Medical Devices, Diagnostics and Healthcare IT that increase connectivity in the healthcare ecosystem. The fund is particularly interest in verticals of Health and Wellness, Chronic Disease Care, Aging in Place, Telemedicine, Genomics, Patient Monitoring, Clinical Trails Management, Mobile Software Healthcare IT Applications, and Electronic Medical Records Management. The fund is willing to invest in devices with 510k pathways however the fund is not currently considering highly invasive medical devices.

The Fund is looking for privately held companies with experienced management teams. The fund generally looks to take a board or observer seat following investment and is willing to both lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An Ireland-based angel group has been operating for 5 years and has invested a total of €15-20 million in 15-20 companies, of which have raised more than €40 million thus far. The group focuses on the life science industry where they have made their largest investments, while also having several deals in other sectors such as energy and social media. The group seeks to make 3-4 investments a year, with an annual investment size of €3-5 million. The group typically invests €500,000-€1 million per company. The group has done syndicates with Scotland in the past, and is potentially open to syndicating with Angels in other locations. The group typically makes investments in Ireland-based companies, though is looking to make new investments in other regions in Europe, USA, and Australia.

The group has a particular focus in medical devices, and is also open to diagnostics, drug delivery, and drug repackaging. The group will not invest in therapeutics, pharmaceuticals, or new small molecules, and is agnostic in terms of phase of development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Taiwan-based investment firm is an evergreen fund and is the venture capital arm of a listed Taiwanese pharmaceutical company. The firm makes direct equity investments into venture stage companies, typically in Series A and B. The initial allocation ranges from $1-5 million. The firm is currently seeking opportunities based in Taiwan, China, Europe and the US.

The firm focuses 50% on therapeutics, 30% on medical devices, and 20% on other health technology. Within therapeutics, the firm considers small molecules and biologics in Oncology, CNS, pain, rare disease, and anti-infectives. The firm typically invests in preclinical projects that have proof-of-concept data and are within 2 years prior to phase 1 trial. Within medical devices, the firm is interested in innovative minimally invasive surgical tools for patient or bedside use such as point-of-care diagnostics.

The firm is looking for experienced management teams with strong scientific expertise and management skills. The firm typically requests a board seat in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com